Find a Clinical Trial

Showing 1 - 10 of 34 Trials

Phase 1 study evaluating combination therapy with the receptor tyrosine kinase inhibitor Pexidartinib (PLX3397) and Sirolimus in patients with unresectable sarcoma and Phase 2 study in malignant peripheral nerve sheath tumors

Principal Investigator:

Gulam A. Manji, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT02584647

Population:

Adult

Phase:

I/II

The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be tolerated and result in shrinking of the cancer or stopping the cancer from growing. In the phase I portion, the maximum tolerate dose of the study drug will be determined. In the Phase II potion, progression free survival will be assessed at the dose level found in Phase I. Participants will continue to take the study drug until they experiance an unacceptable side effect or their disease progresses. Are you Eligible? (Inclusion Criteria) Individuals over the age of 18 with Malignant peripheral nerve...
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma

Contact Number:

212-342-5162

NCT Number:

NCT05218499

Population:

Adult

Phase:

II/III

The purpose of this study is to test the study drug, BI 907828 for safety, effectiveness and side effects when compared to receiving the standard treatment, doxorubicin, in subjects with dedifferentiated liposarcoma (DDLPS). BI 907828 has proven to minimize a critical protein interaction between MDM2 and p53, two proteins in your body, which when their interaction is diminished, can stop the growth of your cancer. Patients with DDLPS are normally prescribed Doxorubicin as their standard treatment once they are diagnosed. The study also aims to find the recommended dose of the study drug, BI...
A phase II study, with a safety lead-in, to evaluate ATX-101, a peptide drug targeting PCNA, in advanced dedifferentiated liposarcoma and leiomyosarcoma

Principal Investigator:

Benjamin Izar, MD

Contact Number:

212-342-5162

NCT Number:

NCT05116683

Population:

Adult

Phase:

II

The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma and leiomyosarcoma. ATX-101 is an intravenous (IV) drug which blocks the interaction of a protein called PCNA with a number of “stress response” proteins. These interactions are thought to be important for cancer cell survival and growth. ATX-101 may disrupt these interactions and therefore help treat the cancer. In this study, all patients will receive the same treatment. Most of the exams, tests, and procedures you will have are...
ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB, ANDENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB, INPATIENTS WITH ADVANCED OR METASTATICUNDIFFERENTIATED PLEOMORPHIC SARCOMA ORMYXOFIBROSARCOMA WHO HAVE PROGRESSED ON PRIORCHEMOTHERAPY

Principal Investigator:

Shaheer A Khan, DO

Contact Number:

212-342-5162

NCT Number:

NCT04480502

Population:

Adult

Phase:

II

The purpose of this research study is to determine the effectiveness and safety of envafolimab, an experimental drug that is not approved for use, when given alone or in combination with ipilimumab to stimulate your immune system to attack cancer cells. Envafolimab is an experimental (investigational) cancer drug that overrides the PD-1/PD-L1 checkpoint, which releases a second brake on immune cells that allows them to attack a cancer cell. This study represents the first time envafolimab will be given to sarcoma patients and the first time envafolimab will be given in combination with...
A phase II trial with a safety lead-in to evaluate the addition of APX005M, a CD40agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advancedsarcoma

Principal Investigator:

Shaheer A Khan, DO

Contact Number:

212-342-5162

NCT Number:

NCT03719430

Population:

Adult

Phase:

II

The purpose of this study is to evaluate the effectiveness of a new investigational drug, APX005M, used in combination with the standard (or “usual”) treatment for these types of sarcoma. The standard treatment is doxorubicin (a chemotherapy) and olaratumab (a “targeted” drug which works against a protein that makes sarcomas grow). The investigators believe that doxorubicin and olaratumab, the standard treatment, may work better when combined with APX005M. The purpose of this clinical trial is to evaluate the safety of doxorubicin, olaratumab and APX005M when used...
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma

Principal Investigator:

Matthew A. Ingham, MD

Contact Number:

212-342-5162

NCT Number:

NCT05269355

Population:

Adult

Phase:

II/III

The purpose of this study is to evaluate the effectiveness and safety of an investigational drug, unesbulin. This investigational drug is being studied in unresectable or metastatic, relapsed or refractory leiomyosarcoma along with Dacarbazine. Dacarbazine is a drug that is FDA-approved for the treatment of other types of cancer and recommended by the cancer treatment guidelines for sarcomas, but is not FDA approved to treat leiomyosarcoma. Are you Eligible? (Inclusion Criteria) • You must be 18 years of age or older. • You must have been previously diagnosed with advanced...
A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma

Contact Number:

212-342-5162

NCT Number:

NCT04979442

Population:

Adult

Phase:

III

You are being invited to take part in a research study that includes studying an investigational drug called milademetan in unresectable or metastatic dedifferentiated liposarcoma. Investigational means it has not yet been approved for marketing by any authority that regulates new medicines. The purpose of this study is to learn about the safety, tolerability and effectiveness of an investigational drug called milademetan as compared to the use of trabectidin. In this study, subjects will be randomly assigned (like flipping a coin) to receive one of two study drugs: milademetan or trabectedin...
RINGSIDE: A Phase 2/3, Randomized, Multicenter Study toEvaluate AL102 in Patients with Progressing Desmoid Tumors

Principal Investigator:

Prabhjot Singh Mundi, MD

Contact Number:

212-342-5162

NCT Number:

NCT04871282

Population:

Adult

Phase:

II/III

You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the “study drug”), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study drug and how your body processes the drug . The study drug works by stopping a chemical pathway in the cells that allows desmoid tumors to grow. It is hoped that by stopping this pathway the study drug will stop desmoid tumor...
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Principal Investigator:

Shaheer A Khan, DO

Contact Number:

212-342-5162

NCT Number:

NCT04340843

Population:

Adult

Phase:

II

This study is being done to answer the following question: Is the combination of the drugs belinostat and SGI-110 (guadecitabine) effective at lowering the chance of your chondrosarcoma growing or spreading? Are you Eligible? (Inclusion Criteria) Have you been diagnosed with chondrosarcoma that cannot be removed by surgery? Are you 18 years of age or older? Are you able to come to the clinic for 5 consecutive days each month to get treatment?
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Principal Investigator:

Shaheer A Khan, DO

Contact Number:

212-342-5162

NCT Number:

NCT04950075

Population:

Adult

Phase:

II

The purpose of this study is to learn aabout the effects of the study drug, INBRX-109 on you, your immune system, and your cancer. This study is being done to understand if INBRX-109 is effective against your chondrosarcoma and how safe this drug is. It works in a similar way as antibodies, which are proteins that are naturally present in the body. Antibodies help the body’s immune system fight diseases such as infections. INBRX-109 works by causing specific cell sensors to initiate the death of cancer cells. This is different from the ways other cancer therapies work. Are you Eligible...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages